CoLucid Pharmaceuticals Inc

Type: Company
Name: CoLucid Pharmaceuticals Inc
First reported Jun 27 2014 - Updated Jun 27 2014 - 1 reports

Global migraine market forecast to be worth US$3.7Bn by 2023

(live-PR.com) - Global Migraine market value to grow modestly by 2023 despite promising new drugs. The global migraine treatment market value is expected to undergo a modest increase over the coming years, climbing from $2.5 billion in 2012 to $3.7 billion ... [Published Live-PR.com - Jun 27 2014]
First reported Jun 24 2014 - Updated Jun 24 2014 - 1 reports

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023 - New Study Released

Boston, MA -- ( SBWIRE ) -- 06/24/2014 -- PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023SummaryThe migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose ... [Published SBWire - Jun 24 2014]
First reported May 23 2014 - Updated May 23 2014 - 2 reports

Research and Markets: Lasmiditan by CoLucid Pharmaceuticals Under Licensing Agreement With Ali Lilly - Forecast and Market Analysis to 2023

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/vrg994/lasmiditan) has announced the addition of the "Lasmiditan (Migraine) - Forecast and Market Analysis to 2023" report to their offering. CoLucid Pharmaceuticals ... [Published Business Wire Professional Services News - May 23 2014]
First reported May 06 2014 - Updated May 06 2014 - 1 reports

CoLucid Pharmaceuticals, Inc., Announces Agreement from the FDA on a Special Protocol Assessment (SPA) for the Phase 3 Trial of Lasmiditan in Migraine Including Patients with Risk Factors for Cardiovascular Disease

DURHAM, N.C., May 6, 2014 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, has reached agreement with the U.S. Food and Drug Administration (FDA) for the planned SAMURAI study.  The objective of this trial is ... [Published PR Newswire: Health - May 06 2014]

Quotes

ILDONG Pharma Chairman and CEO, Jung-chi Lee, Ph D , commented, "We expect CoLucid's innovative drug, Lasmiditan, to be successfully developed under our partnership and be subsequently well positioned to perform in the Korean market and Southeast Asia"

More Content

All (7) | News (3) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Global migraine market forecast to be worth US$... [Published Live-PR.com - Jun 27 2014]
PharmaPoint: Migraine - Global Drug Forecast an... [Published SBWire - Jun 24 2014]
Research and Markets: Lasmiditan by CoLucid Pha... [Published Business Wire Professional Services News - May 23 2014]
Research and Markets: Lasmiditan by CoLucid Pha... [Published Business Wire Health News - May 23 2014]
CoLucid Pharmaceuticals, Inc., Announces Agreem... [Published PR Newswire: Health - May 06 2014]
Decision Resources says increasing use of Aller... [Published PharmaBiz - Dec 05 2013]
CoLucid Pharmaceuticals and ILDONG Pharmaceutic... [Published PR Newswire - Oct 23 2013]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Research and Markets: Lasmiditan by CoLucid Pha... [Published Business Wire Professional Services News - May 23 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/vrg994/lasmiditan) has announced the addition of the "Lasmiditan (Migraine) - Forecast and Market Analysis to 2023" report to their offering. CoLucid Pharmaceuticals ...
Research and Markets: Lasmiditan by CoLucid Pha... [Published Business Wire Health News - May 23 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/vrg994/lasmiditan) has announced the addition of the "Lasmiditan (Migraine) - Forecast and Market Analysis to 2023" report to their offering. CoLucid Pharmaceuticals ...
CoLucid Pharmaceuticals, Inc., Announces Agreem... [Published PR Newswire: Health - May 06 2014]
DURHAM, N.C., May 6, 2014 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, has reached agreement with the U.S. Food and Drug Administration (FDA) for the planned SAMURAI study.  The objective of this trial is ...
1

Press Releases

sort by: Date | Relevance
CoLucid Pharmaceuticals and ILDONG Pharmaceutic... [Published PR Newswire - Oct 23 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.